Use of misoprostol in the treatment of postpartum hemorrhage: a pharmacoepidemiological approach.
| Autor: | Koch DM; Universidade Federal do Paraná, Curitiba, PR, Brazil., Rattmann YD; Universidade Federal do Paraná, Curitiba, PR, Brazil. |
|---|---|
| Jazyk: | English; Portuguese |
| Zdroj: | Einstein (Sao Paulo, Brazil) [Einstein (Sao Paulo)] 2019 Nov 07; Vol. 18, pp. eAO5029. Date of Electronic Publication: 2019 Nov 07 (Print Publication: 2020). |
| DOI: | 10.31744/einstein_journal/2020AO5029 |
| Abstrakt: | Objective: To characterize the use of the drug misoprostol for treatment of postpartum hemorrhage in pregnant women. Methods: A descriptive observational study was carried out with secondary data from pregnant women who used misoprostol to treat postpartum hemorrhage in a reference public maternity, from July 2015 to June 2017. Clinical and sociodemographic profiles of pregnant women, how misoprostol was used and success rate in controling postpartum hemorrhage were characterized. Results: A total of 717 prescriptions of misoprostol were identified. Of these, 10% were for treatment of postpartum hemorrhage. The majority of pregnant women were young adults, married, with complete high school education, white, residing in urban areas, multiparous (68.1%) and 25% had previous cesarean sections. The mean gestational age was 39 weeks and 51.4% had a cesarean section. There was prophylactic use of oxytocin in 47.2% of women. Treatment of postpartum hemorrhage was successful in 84.7% of women. Of these, 79.2% also used oxytocin and 54.2% methylergonovine. Only 13.5% of pregnant women had less than five prenatal visits, and the main cause of postpartum hemorrhage was uterine atony. There were 13 complications after hemorrhage, 15.3% required blood transfusion and there was one case of maternal death. Conclusion: Misoprostol showed to be effective and safe for treating postpartum hemorrhage. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|